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C H A P T E R 1
Virus Dynamics
We all know that Art is not truth. Art is a lie that makes us realize
the truth.
—Pablo Picasso
1.1 FIRST SIGNPOST
The Prologue suggested a three-step procedure to make headway on a scientific problem
(see page 36). Unfortunately, the experiment that can be performed usually does not
directly yield the information we desire, and hence does not directly confirm or disprove
our original hypothesis. For example, this chapter will argue that testing the viral mutation
hypothesis in the Prologue actually requires information not directly visible in the data
that were available in 1995.
Thus, a fourth step is almost always needed:
4. Embody the physical metaphor (or physical model) in mathematical form, and attempt
to fit it to the experimental data.
In this statement, fit means “adjust one or more numbers appearing in the model.” For
each set of these fit parameter values that we choose, the model makes a prediction for
some experimentally measurable quantity, which we compare with actual observations. If
a successful fit can be found, then we may call the model “promising” and begin to draw
tentative conclusions from the parameter values that yield the best fit. This chapter will
take a closer look at the system discussed in the Prologue, illustrating how to construct a
physical model, express it in mathematical form, fit it to data, evaluate the adequacy
of the fit, and draw conclusions. The chapter will also get you started with some of the
basic computer skills needed to carry out these steps.
Each chapter of this book begins with a biological question to keep in mind as you
read, and an idea that will prove relevant to that question.
This chapter’s Focus Question is
Biological question: Why did the first antiviral drugs succeed briefly against HIV, but
then fail?
Physical idea: A physical model, combined with a clinical trial designed to test it,
established a surprising feature of HIV infection.
1.2 MODELING THE COURSE OF HIV INFECTION
We begin with just a few relevant facts about HIV, many of which were known in 1995.
It will not be necessary to understand these in detail, but it is important to appreciate
just how much was already known at that time.
37
38 Chapter 1 Virus Dynamics
1.2.1 Biological background
In 1981, the US Centers for Disease Control noticed a rising incidence of rare diseases
characterized by suppression of the body’s immune system. As the number of patients
dying of normally nonlethal infections rose, it became clear that some new disease, with
an unknown mechanism, had appeared. Eventually, it was given the descriptive name
acquired immune deficiency syndrome (AIDS).
Two years later, research teams in France and the United States showed that a virus
was present in lymph fluid taken from AIDS patients. The virus was named human
immunodeficiency virus (HIV). To understand why HIV is so di cult to eradicate, we
must very briefly outline its mechanism as it was later understood.
HIV consists of a small package (the virus particle, or virion), containing two copies
of the genome, a protective protein shell (or capsid), a few other protein molecules needed
for the initial steps of infection, and a surrounding envelope (see the figure on page 37).
In a retrovirus like HIV, the genome takes the form of RNA molecules, which must be
converted to DNA during the infection.1
The genome of HIV is extremely short, roughly 10 000 bases. It contains nine genes,
which direct the synthesis of just 19 di↵erent proteins. Three of the genes code for proteins
that perform the following functions:2
• gag generates the four proteins that make the virion’s capsid.
• pol generates three protein machines (enzymes): A reverse transcriptase converts the
genome to DNA, an integrase helps to insert the viral DNA copy into the infected cell’s
own genome, and a protease cleaves (cuts) the product of gag (and of pol itself) into
separate proteins (Figure 1.1).
• env generates a protein that embeds itself in the envelope (called gp41), and another
(called gp120; see page 37) that attaches to gp41, protrudes from the envelope, and
helps the virus to target and enter its host.
HIV targets some of the very immune cells that normally protect us from disease. Its
gp120 protein binds to a receptor found on a human immune cell (the CD4+ helper T
cell, or simply “T cell”). Binding triggers fusion of the virion’s envelope with the T cell’s
outer membrane, and hence allows entry of the viral contents into the cell. The virion
includes some ready-to-go copies of reverse transcriptase, which converts the viral genome
to DNA, and integrase, which incorporates the DNA transcript into the host cell’s own
genome. Later, this rogue DNA directs the production of more viral RNA. Some of the
new RNA is translated into new viral proteins. The rest gets packaged with those proteins,
to form several thousand new virions from each infected cell. The new virions escape from
the host cell, killing it and spreading the infection. The immune system can keep the
infection in check for many years, but eventually the population of T cells falls. When it
drops to about 20% of its normal value, then immune response is seriously compromised
and the symptoms of AIDS appear.
The preceding summary is simplified, but it lets us describe some of the drugs that were
available by the late 1980s. The first useful anti-HIV drug, zidovudine (or AZT), blocks
the action of the reverse transcriptase molecule. Other reverse transcriptase inhibitors
have since been found. As mentioned in the Prologue, however, their e↵ects are generally
1The normal direction of information transmission is from DNA to RNA; a retrovirus is so named because
it reverses this flow.
2That is, they are “structural” genes. The other six genes code for transcription factors; see Chapter 9.
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Figure 1.1: [Artist’s reconstructions based on structural data.] Two protein machines needed for HIV replication. Left:
Reverse transcriptase is shown transcribing the viral RNA into a DNA copy. This molecular machine moves along the
RNA (arrow), destroying it as it goes and synthesizing the corresponding DNA sequence. Right: HIV protease cleaves
the polyprotein generated by a viral gene (in this case, gag) into individual proteins. Many antiviral drugs block the
action of one of these two enzymes. [Courtesy David S Goodsell.]
short lived. A second approach targets the protease molecule; protease inhibitors such as
ritonavir result in defective (not properly cleaved) proteins within the virion. The e↵ects
of these drugs also proved to be temporary.
1.2.2 An appropriate graphical representation can bring out key features of data
Clearly, HIV infection is a complex process. It may seem that the only way to checkmate
such a sophisticated adversary is to keep doggedly looking for, say, a new protease inhibitor
that somehow works longer than the existing ones.
But sometimes in science the intricate details can get in the way of the viewpoint shift
that we need for a fresh approach. For example, the Prologue described a breakthrough
that came only after appreciating, and documenting, a very basic aspect of HIV infection:
its ability to evolve rapidly in a single patient’s body.
The Prologue suggested that fast mutation is possible if the viral replication rate
is high, and that this rate could be determined by examining the fallo↵ of viral load
when production was halted by a drug. The graph in Figure 0.3 is drawn in a way that
Figure 0.3 (page 35) makes a particular behavior manifest: Instead of equally spaced tick marks representing
uniform intervals on the vertical axis, Figure 0.3 uses a logarithmic scale. That is, each
point is drawn at a height above the horizontal axis that is proportional to the logarithm
of virus population. (The horizontal axis is drawn with an ordinary linear scale.) The
resulting semilog plot makes it easy to see when a data series is an exponential function of
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time:3 The graph of the function f(t) = C exp(kt) will appear as a straight line, because
ln f(t) = (lnC) + kt is a linear function of t.
Your
Turn
1A
Does this statement depend on whether we use natural or common
logarithms?
Log axes are usually labeled at each power of 10, as shown in Figure 0.3. The unequally
spaced “minor” tick marks between the “major” ones in the figure are a visual cue,
alerting the reader to the log feature. Most computer math packages can create such axes
for you. Note that the tick marks on the vertical axis in Figure 0.3 represent 1000, 2000,
3000, . . . , 9000, 10 000, 20 000, 30 000, . . . , 900 000, 1 000 000. In particular, the next tick
after 104 represents 2 · 104, not 11 000, and so on.
1.2.3 Physical modeling begins by identifying the key actors and their main interactions
Although the data shown in Figure 0.3 are suggestive, they are not quite what we need to
establish the hypothesis of rapid virus mutation. The main source of mutations is reverse
transcription.4 Reverse transcription usually occurs only once per T cell infection. So
if we wish to establish that there are many opportunities for mutation, then we need
to show that many new T cell infections are occurring per unit time. This is not the
same thing as showing that new virions are being created rapidly, so we must think more
carefully about what we can learn from the data. Simply making a graph is not enough.
Moreover, the agreement between the data (dots in Figure 0.3) and the simple
Figure 0.3 (page 35) expectation of exponential fallo↵ (line) is actually not very good. Close inspection
shows that the rapid fall of virus population does not begin at the moment the drug
is administered (“time 0”). Instead, the data shown in the figure (and similar graphs
from other patients) show an initial pause in virus population at early times, prior to the
exponential drop. It’s not surprising, really—so far we haven’t even attempted to write
any quantitative version of our initial intuition.
To do better than this, we begin by identifying the relevant processes and quantities
a↵ecting virus population. Infected T cells produce free virions, which in turn infect
new cells. Meanwhile, infected T cells eventually die, and the body’s defenses also kill
them; we will call the combined e↵ect clearance of infected cells. The immune system
also destroys free virions, another kind of clearance. To include these processes in our
model, we first assign names to all the associated quantities. Thus, let t be time after
administering the antiviral drug. Let NI(t) be the number of infected T cells at time t,
and NV(t) the number of free virions in the blood (the viral load).5
Before drug treatment (that is, at time t < 0), production and removal processes
roughly balance, leading to a nearly steady (quasi-steady) state, the long period of low
virus population seen in Figure 0.1. In this state, the rate of new infections must balance
Figure 0.1 (page 33)
3The prefix “semi-” reminds us that only one axis is logarithmic. A “log-log plot” uses logarithmic scales
on both axes; we’ll use this device later to bring out a di↵erent feature in other datasets.
4The later step of making new viral genomes from the copy integrated into the T cell’s DNA is much
more accurate; we can neglect mutations arising at that step.
5The concentration of virions is therefore NV(t) divided by the blood volume. Because the blood volume
is constant in any particular patient, we can work with either concentration or total number.
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Figure 1.2: [Schematic.] Simplified virus life cycle. In this model, the e↵ect of antiviral drug
therapy is to halt new infections of T cells (cross). The constants kI, kV,   introduced in the text
are shown at the points of action of the associated processes.
T cell clearance—so finding their rate of clearance will tell us the rate of new infections
in the quasi-steady state, which is what we are seeking.
Let’s idealize the system by assuming that the antiviral drug completely stops new
infections of T cells. From that moment, uninfected T cells become irrelevant—they
“decouple” from infected T cells and virions. We also simplify by assuming that each
infected T cell has a fixed chance of being cleared in any short time interval. That
chance depends on the duration  t of the interval, and it becomes zero if  t = 0, so
it’s reasonable to suppose that it’s the product of  t times a constant, which we’ll call
kI.6 These assumptions imply that, after administering the drug, NI changes with time
according to a simple equation:
dNI
dt
=  kINI for t   0. (1.1)
In this formula, the clearance rate constant kI is a free parameter of the model—we don’t
know its value in advance. Notice that it appears multiplied by NI: The number lost
between t and t+ t depends on the total number present at time t, as well as on the
rate constant and  t.
Simultaneously with the deaths of infected T cells, virions are also being produced
and cleared. Similarly to what we assumed for NI, suppose that each virion has a fixed
probability per unit time to be cleared, called kV, and also that the number produced
in a short interval  t is proportional to the population of infected T cells. Writing the
number produced per time as  NI, where the constant of proportionality   is another
free parameter, we can summarize our physical model by supplementing Equation 1.1
with a second equation:
dNV
dt
=  kVNV +  NI. (1.2)
Figure 1.2 summarizes the foregoing discussion in a cartoon. For reference, the
following quantities will appear in our analysis:
6 T2 We are ignoring the possibility of saturation, that is, decrease in clearance probability per infected
cell per unit time when the concentration of infected cells is so high that the immune system is overloaded.
This assumption will not be valid in the late stages of infection. We also assume that an infected T cell is
unlikely to divide before being cleared.
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t time since administering drug
NI(t) population of infected T cells; its initial value is NI0
NV(t) population of virions; its initial value is NV0
kI clearance rate constant for infected T cells
kV clearance rate constant for virions
  rate constant for virion production per infected T cell
  an abbreviation for  NI0
1.2.4 Mathematical analysis yields a family of predicted behaviors
With the terminology in place, we can describe our plan more concretely than before:
• We want to test the hypothesis that the virus evolves within a single patient.
• To this end, we’d like to find the rate at which T cells get infected in the quasi-steady
state, because virus mutation is most likely to happen at the error-prone reverse
transcription step, which happens once per infection.
• But the production rate of newly infected T cells was not directly measurable in 1995.
The measurable quantity was the viral load NV as a function of time after administering
the drug.
• Our model, Equations 1.1–1.2, connects what we’ve got to what we want, because (i) in
the quasi-steady state, the infection rate is equal to the rate kI at which T cells are lost,
and (ii) kI is a parameter that we can extract by fitting the model in Equations 1.1–1.2
to data about the non-steady state after administering an antiviral drug.
Notice that Equation 1.1 doesn’t involve NV at all; it’s one equation in one unknown
function, and a very famous one too. Its solution is exponential decay: NI(t) = NI0e kIt.
The constant NI0 is the initial number of infected T cells at time zero. We can just
substitute that solution into Equation 1.2 and then forget about Equation 1.1. That is,
dNV
dt
=  kVNV +  NI0e kIt. (1.3)
Here kI, kV,  , and NI0 are four unknown quantities. But we can simplify our work by
noticing that two of them enter the equation only via their product. Hence, we can
replace   and NI0 by a single unknown, which we’ll abbreviate as   =  NI0. Because the
experiments did not actually measure the population of infected T cells, we need not
predict it, and hence we won’t need the separate values of   and NI0.
We could directly solve Equation 1.3 by the methods of calculus, but it’s usually
best to try for an intuitive understanding first. Think about the metaphor in Figure 0.2,
where the volume of water in the middle chamber at any moment plays the role of NV.
For a real leaky container, the rate of outflow depends on the pressure at the bottom,
and hence on the level of the water; similarly, Equation 1.2 specifies that the clearance
(outflow) rate at time t depends on NV(t). Next, consider the inflow: Instead of being a
constant equal to the outflow, as it is in the steady state, Equation 1.3 gives the inflow
rate as  e kIt (see Figure 0.2).
 e kit
 kvNv
Nv
Figure 0.2 (page 34) Our physical metaphor now lets us guess some general behavior. If kI   kV, then
we get a burst of inflow that quickly shuts o↵, before much has had a chance to run
out. So after this brief transient behavior, NV should fall exponentially with time, in a
way controlled by the decay rate constant kV. In the opposite extreme case, kV   kI,
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the container drains nearly as fast as it’s being filled;7 the water level simply tracks the
inflow. Thus, again the water level falls exponentially, but this time in a way controlled
by the inflow decay rate constant kI.
Our intuition from the preceding paragraph suggests that the long-time behavior of
the solution to Equation 1.3 is proportional either to e kIt or e kVt, depending on which
rate constant is smaller. We can now try to guess a trial solution with this property. In
fact, the function
NV(t)
?
=Xe kIt + (NV0  X)e kVt, (1.4)
where X is any constant value, has the desired behavior. Moreover, Equation 1.4 equals
NV0 at time zero. We now ask if we can choose a value of X that makes Equation 1.4 a
solution to Equation 1.3. Substitution shows that indeed it works, if we make the choice
X =  /(kV   kI).
Figure 0.3 (page 35)
Your
Turn
1B
a. Confirm the last statement.
b. The trial solution, Equation 1.4, seems to be the sum of two
terms, each of which decreases in time. So how could it have the
initial pause that is often seen in data (Figure 0.3)?
T2 Section 1.2.4
0 (page 51) discusses the hypothesis of viral evolution within a single patient
in greater detail.
1.2.5 Most models must be fitted to data
What has been accomplished so far? We proposed a physical model with three unknown
parameters, kI, kV, and  . One of these, kI, is relevant to our hypothesis that virus is
rapidly infecting T cells, so we’d like to know its numerical value. Although the population
of infected T cells was not directly measurable in 1995, we found that the model makes a
prediction for the virus number NV(t), which was observable then. Fitting the model to
experimentally measured virus concentration data can thus help us determine the desired
rate constant kI.
The math gave a prediction for NV(t) in terms of the initial viral load NV0 and the
values of kI, kV, and  . The prediction does have the observed qualitative behavior that
after an initial transient, NV(t) falls exponentially, as seen in Figure 0.3. The remaining
Figure 0.3 (page 35) challenges are that
• We haven’t yet determined the unknowns kI, kV, and  .
• The model itself needs to be evaluated critically; all of the assumptions and approxima-
tions that went into it are, in principle, suspect.
To gain some confidence in the model, and find the unknown parameter values, we must
attempt a detailed comparison with data. We would especially hope to find that di↵erent
patients, despite having widely di↵erent initial viral load NV0, nevertheless all have similar
values of kI. Then the claim that this rate is “very large” (and hence may allow for virus
evolution in a single patient) may have some general validity.
7The water never drains completely, because in our model the rate of outflow goes to zero as the height
goes to zero. This may not be a good description of a real bucket, but it’s reasonable for a virus, which
becomes harder for the immune system to find as its concentration decreases.
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Figure 1.3: [Experimental data.] Bad fits. Dots are the same experimental data that appeared in Figure 0.3 (page 35).
The solid curve shows the trial solution to our model (Equation 1.4), with a bad set of parameter values. Although the
solution starts out at the observed value, it quickly deviates from the data. However, a di↵erent choice of parameters
does lead to a function that works (see Problem 1.4). The dashed curve shows a fit to a di↵erent functional form, one
not based on any physical model. Although it starts and ends at the right values, in fact, no choice of parameters for
this model can fit the data.
Certainly it’s not di cult to find things that don’t work! Figure 1.3 shows the
experimental data, along with two functions that don’t fit them. One of these functions
belongs to the class of trial solutions that we constructed in the preceding section. It
looks terrible, but in fact you’ll show in Problem 1.4 that a function of this form can be
made to look like the data, with appropriate choices of the fitting parameters. The other
function shown in the figure is an attempt to fit the data with a simple linear function,
NV(t)
?
=A Bt. We can make this function pass through our data’s starting and ending
points, but there is no way to make it fit all of the data. It’s not surprising—we have no
physical model leading us to expect a linear fallo↵ with time. If we were considering such
a model, however, our inability to fit it would have to be considered as strong evidence
that it is wrong.
After you work through Problem 1.4, you’ll have a graph of the best-fitting version of
the model proposed in the preceding section. Examining it will let you evaluate the main
hypothesis proposed there, by drawing a conclusion from the fit parameter values.
1.2.6 Overconstraint versus overfitting
Our physical model includes crude representations of some processes that we knew
must be present in our system, although the model neglects others. It’s not perfect,
but the agreement between model and data that you’ll find in Problem 1.4 is detailed
enough to make the model seem “promising.” Fitting the model requires that we adjust
three unknown parameters, however. There is always the possibility that a model is
fundamentally wrong (omits some important features of reality) but nevertheless can
be made to look good by tweaking the values of its parameters. It’s a serious concern,
because in that case, the parameter values that gave the fortuitously good fit can be
meaningless. Concerns like these must be addressed any time we attempt to model any
system.
In our case, however, Problem 1.4 shows that you can fit more than three data points
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by an appropriate choice of three parameters. We say that the data overconstrain the
model, because there are more conditions to be met than there are parameters to adjust.
When a model can match data despite being overconstrained, that fact is unlikely to
be a coincidence. The opposite situation is often called overfitting; in extreme cases, a
model may have so many free fit parameters that it can fit almost any data, regardless of
whether it is correct.
Successfully fitting an overconstrained model increases our confidence that it reflects
reality, even if it proposes the existence of hidden actors, for which we may have little or
no direct evidence. In the HIV example, these actors were the T cells, whose population
was not directly observable in the original experiments.
T2 Section 1.2.6
0 (page 51) discusses in more detail the sense in which our model is overcon-
strained, and outlines a more realistic model for virus dynamics.
1.3 JUST A FEW WORDS ABOUT MODELING
Sometimes we examine experimental data, and their form immediately suggests some
simple mathematical function. We can write down that function with some parameters, plot
it alongside the data, and adjust the parameters to optimize the fit. In Problem 1.5 you’ll
use this approach, which is sometimes called “blind fitting.” Superficially, it resembles
what we did with HIV data in this chapter, but there is a key di↵erence.
Blind fitting is often a convenient way to summarize existing data. Because many
systems respond continuously as time progresses or a parameter is changed, choosing a
simple smooth function to summarize data also lets us interpolate (predict what would
have been measured at points lying between actual measurements). But, as you’ll see
in Problem 1.5, blind fitting often fails spectacularly at extrapolation (predicting what
would have been measured at points lying outside the range of actual measurements).8
That’s because the mathematical function that we choose may not have any connection
to any underlying mechanism giving rise to the behavior.
This chapter has followed a very di↵erent procedure. We first imagined a plausible
mechanism consistent with other things we knew about the world (a physical model),
and then embodied it in mathematical formulas. The physical model may be wrong; for
example, it may neglect some important players or interactions. But if it gives nontrivial
successful predictions about data, then we are encouraged to test it outside the range
of conditions studied in the initial experiments. If it passes those tests as well, then it’s
“promising,” and we are justified in trying to apply its results to other situations, di↵erent
from the first experiments. Thus, successful fitting of a model to HIV data suggested a
successful treatment strategy (the multidrug treatment described in the Prologue). Other
chapters in this book will look at di↵erent stories.
In earlier times, a theoretical “model” often just meant some words, or a cartoon.
Why must we clutter such images with math? One reason is that equations force a model
to be precise, complete, and self-consistent, and they allow its full implications to be
worked out, including possible experimental tests. Some “word models” sound reasonable
8Even interpolation can fail: We may have so few data points that a simple function seems to fit them,
even though no such relation exists in reality. A third pitfall with blind fitting is that, in some cases, a
system’s behavior does not change smoothly as parameters are changed. Such “bifurcation” phenomena
are discussed in Chapter 10.
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but, when expressed precisely, turn out to be self-inconsistent, or to depend on physically
impossible values for some parameters. In this way, modeling can formulate, explore, and
often reject potential mechanisms, letting us focus only on experiments that test the
promising ones.
Finally, skillful modeling can tell us in advance whether an experiment is likely to
be able to discriminate two or more of the mechanisms under consideration, or point
to what changes in the experimental design will enhance that ability. For that reason,
modeling can also help us make more e cient use of the time and money needed to
perform experiments.
THE BIG PICTURE
This chapter has explored a minimal, reductionist approach to a complex biological system.
Such an approach has strengths and weaknesses. One strength is generality: The same
sort of equations that are useful in understanding the progression of HIV have proven to
be useful in understanding other infections, such as hepatitis B and C.
More broadly, we may characterize a good scientific experience as one in which a
puzzling result is explained in quantitative detail by a simplified model, perhaps involving
some sort of equations. But a great scientific experience can arise when you find that
some totally di↵erent-seeming system or process obeys the same equations. Then you
gain insights about one system from your experience with the other. In this chapter, the
key equations had associations with systems like leaky containers, which helped lead us
to the desired solution.
Our physical model of HIV dynamics still has a big limitation, however. Although the
fit to data supports the picture of a high virus production rate, this does not completely
validate the overall picture proposed in the Prologue (page 36). That proposal went on
to assert that high production somehow leads to the evolution of drug resistance. In fact,
although this connection is intuitive, the framework of this chapter cannot establish it
quantitatively. When writing down Equations 1.1–1.2, we tacitly made the assumption
that T cell and virus populations were quantities that changed continuously in time. This
assumption allowed us to apply some familiar techniques from calculus. But really, those
populations are integers, and so must change discontinuously in time.
In many situations, the di↵erence is immaterial. Populations are generally huge
numbers, and their graininess is too small to worry about. But in our problem we are
interested in the rare, chance mutation of just one virion from susceptible to resistant
(Figure 1.4). We will need to develop some new methods, and intuition, to handle such
problems.
The word “chance” in the preceding paragraph highlights another gap in our under-
standing so far: Our equations, and calculus in general, describe deterministic systems,
ones for which the future follows inevitably once the present is su ciently well known.
It’s an approach that works well for some phenomena, like predicting eclipses of the
Sun. But clockwork determinism is not very reminiscent of Life. And even many purely
physical phenomena, we will see, are inherently probabilistic in character. Chapters 3–7
will develop the ideas we need to introduce randomness into our physical models of living
systems.
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Figure 1.4: [Artist’s reconstructions based on structural data.] Antiviral drugs are molecules that bind tightly to HIV’s
enzymes and block their action. HIV protease can become resistant to drugs by mutating certain of its amino acids; such
a mutation changes its shape slightly, degrading the fit of the drug molecule to its usual binding site. The drug ritonavir
is shown in green. Left: The amino acids at position 82 in each of the enzyme’s two protein chains are normally valines
(magenta); they form close contacts with the drug, stabilizing the binding. The bound drug molecule then obstructs
the enzyme’s active site, preventing it from carrying out its function (see Figure 1.1 (page 41)). Right: In the mutant
enzyme, this amino acid has been changed to the smaller alanine (red), weakening the contact slightly. Ritonavir then
binds poorly, and so does not interfere with the enzyme’s activity even when it is present. [Courtesy David S Goodsell.]
KEY FORMULAS
Throughout the book, closing sections like this one will collect useful formulas that
appeared in each chapter. In this chapter, however, the section also includes formulas
from your previous study of math that will be needed later on.
• Mathematical results: Make sure you recall these Taylor series and how they follow
from Taylor’s theorem. Some are valid only when x is “small” in some sense.
exp(x) = 1 + x+ · · ·+ 1
n!
xn + · · ·
cos(x) = 1  1
2!
x2 +
1
4!
x4   · · ·
sin(x) = x  1
3!
x3 +
1
5!
x5 · · ·
1/(1  x) = 1 + x+ · · ·+ xn + · · ·
ln(1  x) =  x  1
2
x2   · · ·  1
n
xn   · · ·
p
1 + x = 1 +
1
2
x  1
8
x2 + · · ·
In addition, we’ll later need these formulas:
The binomial theorem: (x+y)M = CM,0xMy0+CM,1xM 1y1+ · · ·+CM,Mx0yM , where
the binomial coe cients are given by
CM,` =M !/
 
`!(M   `)!  for ` = 0, . . . ,M.
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The Gaussian integral:
R1
 1 dx exp( x2) =
p
⇡.
The compound interest formula:9 limM!1
 
1 + aM
 M
= exp(a).
• Continuous growth/decay: The di↵erential equation dNI/dt = kNI has solution NI(t) =
NI0 exp(kt), which displays exponential decay (if k is negative) or growth (if k is positive).
• Viral dynamics model: After a patient begins taking antiviral drugs, we proposed a
model in which the viral load and population of infected T cells are solutions to
dNI
dt
=  kINI for t   0, (1.1)
dNV
dt
=  kVNV +  NI. (1.2)
FURTHER READING
Semipopular:
On overfitting: Silver, 2012, chapt. 5.
Intermediate:
HIV: Freeman & Herron, 2007.
Modeling and HIV dynamics: Ellner & Guckenheimer, 2006, §6.6; Nowak, 2006; Otto &
Day, 2007, chapt. 1; Shonkwiler & Herod, 2009, chapt. 10.
Technical:
Ho et al., 1995; Nowak & May, 2000; Perelson & Nelson, 1999; Wei et al., 1995. Equa-
tions 1.1 and 1.2 appeared in Wei et al., 1995, along with an analysis equivalent to
Section 1.2.4.
9The left side of this formula is the factor multiplying an initial balance on a savings account after one
year, if interest is compounded M times a year at an annual interest rate a.
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1.2.40 Exit from the latency period via proliferation of mutants
Prior to the events of 1995, Nowak, May, and Anderson had already developed a theory
for the general behavior shown in Figure 0.1 (see Nowak, 2006, chapt. 10). According to
Figure 0.1 (page 33) this theory, during the initial spike in viral load, one particular strain of HIV becomes
dominant, because it reproduces faster than the others. The immune system manages to
control this one strain, but over time it mutates, generating diversity. Eventually, the
immune system gets pushed to a point beyond which it is unable to cope simultaneously
with all the strains that have evolved by mutation, and the virus concentration rises
rapidly. Meanwhile, each round of mutation stimulates a new class of T cells to respond,
more and more of which are themselves already infected, weakening their response.
T2 Track 2
1.2.60a Informal criterion for a falsifiable prediction
The main text stated that our result was significant because we could fit many (more than
three) data points by adjusting only three unknown parameters: kI, kV, and  . It’s a bit
more precise to say that the data in Figure 0.3 have several independent “visual features”:
Figure 0.3 (page 35) the slope and intercept of the final exponential decay line, the initial slope and value NV0,
and the sharpness of the transition from initial plateau to exponential decay. Of these
five features, NV0 was already used in writing the solution, leaving four that must be fit
by parameter choice. But we have only three parameters to adjust, which in principle
makes our trial solution a falsifiable prediction: There is no mathematical guarantee that
any choice of parameters can be found that will fit such data. If we do find a set of values
that fit, we may at least say that this experiment has missed an opportunity to falsify
the model, increasing our confidence that the model may be correct. In this particular
case, none of the visual features are very precisely known, due to scatter in the data and
the small number of data points available. Thus, we can only say that (i) the data are
not qualitatively inconsistent with the model, but (ii) the data are inconsistent with the
value (kI)
 1 ⇡ 10 years suggested by the hypothesis of a slow virus.
1.2.60b More realistic viral dynamics models account for partially-e↵ective drugs
Many improvements to the model of HIV dynamics in the main text have been explored.
For example, we supposed that no new infections occur after administering the drug, but
neither of the drug classes mentioned in the text work in exactly this way. Some instead
block reverse transcription after virus entry; such a drug may be only partially e↵ective,
so that new infections of T cells continue, at a reduced rate, after administration of the
drug. Other drugs seek to stop the production of “competent” virions; these, too, may be
only partly e↵ective. A more complex set of equations incorporating these ideas appeared
in Perelson (2002). Letting NU(t) be the population of uninfected T cells and NX(t) that
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of inactive virions, the model becomes
dNU
dt
=    kVNU   ✏NVNU, (1.5)
dNI
dt
= ✏NVNU   kINI, (1.6)
dNV
dt
= ✏0 NI   kVNV, (1.7)
dNX
dt
= (1  ✏0) NI   kVNX. (1.8)
Here, the normal birth and death of T cells are described by the constants   and kV,
respectively, the residual infectivity by ✏, and the fraction of competent virions produced
by ✏0.
Even this more elaborate model makes assumptions that are not easy to justify. But
it can account nicely for a lot of data, including the fact that at longer times than those
shown in Figure 0.3, virus concentration stops dropping exponentially.
Figure 0.3 (page 35)
1.2.60c Latently-infected cells make eradication of HIV di cult
Unfortunately, not all infected cells are short lived. The cell death rate that we found
from the math reflects only the subset of infected cells that actively add virions to the
blood; but some infected cells do not. Some of the other, nonproductive infected cells
have a latent “provirus” in their genome, which can be activated later. That’s one reason
why complete eradication of HIV remains di cult.
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PROBLEMS
1.1 Molecular graphics
You can make your own molecular graphics. Access the Protein Data Bank (Media 310).
The simplest way to use it is to enter the name or code of a macromolecule in the search
box. Then click “3D view” on the right and manipulate the resulting image. Alternatively,
you can download coordinate data for the molecule to your own computer and then
visualize it by using one of the many free software packages listed in Media 3. To find
some interesting examples, you can explore the past Molecules of the Month or see page
400 for the names of entries used in creating images in this book.
a. Make images based on the following entries, which are relevant to the present chapter:
• 1jlb (HIV-1 reverse transcriptase in complex with nevirapine)
• 1hsg (HIV-2 protease complexed with a protease inhibitor)
• 1rl8 (resistant strain of HIV-1 protease with ritonavir)
b. Now try these entries, which are molecules to be discussed in Chapter 10:
• 1lbh (lac repressor bound to the gratuitous inducer IPTG)
• 3cro (Cro transcription factor, bound to a segment of DNA)
• 1pv7 (lactose permease bound to the lactose-like molecule TDG)
c. These entries are also interesting:
• 1mme (hammerhead ribozyme)
• 2f8s (small interfering RNA)
1.2 Semilog and log-log plots
a. Use a computer to plot the functions f1(x) = exp(x) and f2(x) = x3.5 on the range
2  x  7. These functions may appear qualitatively similar.
b. Now make semilogarithmic graphs of the same two functions. What outstanding feature
of the exponential function jumps out in this representation?
c. Finally, make log-log graphs of the two functions and comment.
1.3 Half-life
Sometimes instead of quoting a rate constant like kI in Equation 1.1 (page 43), scientists
will quote a half-life, the time after which an exponentially falling population has decreased
to half its original value. Derive the relation between these two quantities.
1.4 Model action of antiviral drug
Finish the analysis of the time course of HIV infection after administering an antiviral
drug. For this problem, you may assume that virus clearance is faster than T cell death
(though not necessarily much faster). That is, assume kV > kI.
a. Follow Section 1.2.4 (page 44) to write down the trial solution for NV(t), the observable
quantity, in terms of the initial viral load NV0 and three unknown constants kI, kV,
and  .
b. Obtain Dataset 1,11 and use a computer to make a semilog plot. Don’t join the points
by line segments; make each point a symbol, for example, a small circle or plus sign.
10References of this form refer to Media links on the book’s Web site.
11References of this form refer to Dataset links on the book’s Web site.
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Label the axes of your plot. Give it a title, too. Superimpose a graph of the trial
solution, with some arbitrary values of kI, kV, and  , on your graph of the actual
data. Then try to fit the trial solution to the data, by choosing better values of the
parameters.
c. You may quickly discover that it’s di cult to find the right parameter values just
by guessing. Rather than resort to some black-box software to perform the search,
however, try to choose parameter values that make certain features of your graph
coincide with the data, as follows. First, note that the experimental data approach a
straight line on a semilog plot at long times (apart from some experimental scatter).
The trial solution Equation 1.4 also approaches such a line, namely, the graph of the
function NV,asymp(t) = Xe kIt, so you can match that function to the data. Lay a
ruler along the data, adjust it until it seems to match the long-time trend of the data,
and find two points on that straight line. From this information, find values of kI and
X that make NV,asymp(t) match the data.
d. Substitute your values of kI and X into Equation 1.4 (page 45) to get a trial solution
with the right initial value NV0 and the right long-time behavior. This is still not
quite enough to give you the value of kV needed to specify a unique solution. However,
the model suggests another constraint. Immediately after administering the drug, the
number of infected T cells has not yet had a chance to begin falling. Thus, in this
model both viral production and clearance are the same as they were prior to time
zero, so the solution is initially still quasi-steady:
dNV
dt
    
t=0
= 0.
Use this constraint to determine all parameters of the trial solution from your answer to
(c), and plot the result along with the data. (You may want to tweak the approximate
values you used for NV0, and other parameters, in order to make the fit look better.)
e. The hypothesis that we have been exploring is that the reciprocal of the T cell infection
rate is much shorter than the typical latency period for the infection, or in other words
that
(1/kI) is much smaller than 10 years.
Do the data support this claim?
f. Use your result from Problem 1.3 to convert your answers to (d) into half-life values
for virions and infected T cells. These represent half-lives in a hypothetical system
with clearance, but no new virion production nor new infections.
1.5 Blind fitting
Obtain Dataset 2. This file contains an array consisting of two columns of data. The first
is the date in years after an arbitrary starting point. The second is the estimated world
population on that date.
a. Use a computer to plot the data points.
b. Here is a simple mathematical function that roughly reproduces the data:
f(t) =
100 000
2050  (t/1 year) . (1.9)
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Have your computer draw this function, and superimpose it on your graph of the
actual data. Now play around with the function, trying others of the same form
f(t) = A/(B   t), for some constants A and B. You can get a pretty good-looking fit
in this way. (There are automated ways to do this, but it’s instructive to try it “by
hand” at least once.)
c. Do you think this is a good model for the data? That is, does it tell us anything
interesting beyond roughly reproducing the data points? Explain.
1.6 T2 Special case of a di↵erential equation system
Consider the following system of two coupled linear di↵erential equations, simplified a bit
from Equations 1.1 and 1.2 on page 43:
dA/dt =  kAA and dB/dt =  kBB +A.
This set of equations has two linearly independent solutions, which can be added in any
linear combination to get the general solution.12 So the general solution has two free
parameters, the respective amounts of each independent solution.
Usually, a system of linear di↵erential equations with constant coe cients has solutions
in the form of exponential functions. However, there is an exceptional case, which can
arise even in the simplest example of two equations. Remember the physical analogy for
this problem: The first equation determines a function A(t), which is the flow rate into a
container B, which in turn has a hole at the bottom.
Section 1.2.4 argued that if kA ⌧ kB , then B can’t accumulate much, and its outflow
is eventually determined by kA. In the opposite case, kB ⌧ kA, B fills up until A runs out,
and then trickles out its contents in a way controlled by kB. Either way, the long-time
behavior is an exponential, and in fact we found that at all times the behavior is a
combination of two exponentials.
But what if kA = kB? The above reasoning is inapplicable in that case, so we can’t
be sure that every solution falls as an exponential at long times. In fact, there is one
exponential solution, which corresponds to the situation where A(0) = 0, so we have only
B running out. But there must also be a second, independent solution.
a. Find the other solution when kA = kB, and hence find the complete general solution
to the system. Get an analytic result (a formula), not a numerical one. [Hint: Solve
container A’s behavior explicitly: A(t) = A0 exp( kAt), and substitute into the other
equation to get
dB/dt =  kAB +A0 exp( kAt).
If A0 6= 0, then no solution of the form B(t) = exp( kAt) works. Instead, play around
with multiplying that solution by various powers of t until you find something that
solves the equation.]
b. Why do you suppose this case is not likely to be relevant to a real-life problem like
our HIV story?
1.7 T2 Infected cell count
First, work Problem 1.4. Then continue as follows to get an estimate of the population of
infected T cells in the quasi-steady state. Chapter 3 will argue that this number is needed
in order to evaluate the hypothesis of viral evolution in individual patients.
12In general, a system of N first-order linear di↵erential equations in N unknowns has N independent
solutions.
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a. The human body contains about 5 L of blood. Each HIV virion carries two copies of
its RNA genome. Thus, the total virion population is about 2.5 · 103mL times the
quantity plotted in Figure 0.3. Express the values of NV0 and X that you found in
Figure 0.3 (page 35)
Problem 1.4 in terms of total virion population.
b. Obtain a numerical estimate for   from your fit. (You found the value of kI in
Problem 1.4.)
c. The symbol   is an abbreviation for the product  NI0, where   ⇡ 100kI is the rate of
virion release by an infected T cell and NI0 is the quantity we want to find. Turn your
results from (a) and (b) into an estimate of NI0.
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